Seretide Evohaler fluticasone propionate 50mcg + salmeterol xinafoate 25mcg per actuation

3 trials

Sponsors

Prosonix Limited

Conditions

Respiratory Healthy subjects, intended disorder is asthma

Unknown Phase

Systemic exposure bio equivalence study between 2 formulations of orally inhaled fluticasone propionate and salmeterol xinafoate

Active, not recruitingPACTR201506001172164

Prosonix LimitedRespiratory Healthy subjects, intended disorder is asthma

Start: 2015-07-16Target: 60Updated: 2026-09-14

Systemic exposure bioequivalence study between two formulations of orally inhaled fluticasone propionate and salmeterol xinafoate.

Active, not recruitingPACTR201508001221356

Prosonix LimitedRespiratory Healthy subjects, intended disorder is asthma

Start: 2015-09-10Target: 60Updated: 2026-09-14

Systemic exposure bioequivalence study betwn two formulations of orally inhaled fluticasone propionate and salmeterol xinafoate

Active, not recruitingPACTR201508001240411

Prosonix LimitedRespiratory Healthy subjects, intended disorder is asthma

Start: 2015-07-30Target: 60Updated: 2026-09-14